GLOBAL NON OPIOID PAIN TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Non Opioid Pain Treatment Market Size and Trends

Global non opioid pain treatment market is estimated to be valued at USD 78.89 billion in 2024 and is expected to reach USD 140.56 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.

To learn more about this report, request sample copy

Global non opioid pain treatment market is expected to witness positive growth over the forecast period. There is an increased demand for alternative pain therapies owing to the risks and side effects associated with opioid medications. Moreover, growing geriatric population who are more prone to chronic pain conditions like arthritis, and rising awareness about the benefits of non opioid options are some key factors driving the growth of the market. However, high treatment cost of some non opioid therapies and lack of medical reimbursements may hinder the market growth. Overall, advancement in drug delivery technologies and novel product pipeline are expected to bring new opportunities for the market.

Rising Prevalence of chronic conditions

As the population ages, the prevalence of various chronic conditions such as osteoarthritis, lower back pain, and fibromyalgia is rising across regions. Chronic pain leads to a significant reduction in the quality of life as it causes difficulties carrying out routine tasks and disrupts normal sleep patterns. According to a study published in May 2023, by National Institutes of Health, primary agency of the U.S. government that is responsible for biomedical and public health research, new cases of chronic pain are more common among U.S. adults than new cases of diabetes, depression, or high blood pressure. Nearly two-thirds of persons with chronic pain continue to suffer from it a year later. The number of new chronic pain cases was high in 2020, with 52.4 instances per 1,000 people per year. This is in contrast to other frequent chronic illnesses such as diabetes (7.1 cases/1,000 per year), depression (15.9 cases/1,000 per year), and hypertension (45.3 cases/1,000 per year).

The ongoing public health crisis arising from misuse and overprescription of opioid medicines in countries like U.S. has brought the drawbacks of opioids under intense global scrutiny. Various entities ranging from public health organizations to governments are engaged in initiatives aimed at curbing inappropriate usage of these highly addictive drugs. At the same time, educational programs are being conducted to spread awareness among patients and medical practitioners about risks of long term use of opioids, alternative treatment options and importance of achieving an optimal pain treatment regimen. For instance, in August 2023, On International Overdose Awareness Day, the Biden-Harris administration announced August 27–September 2 as Overdose Awareness Week to draw attention to the damage caused by illicit fentanyl and other drugs. The White House Office of National Drug Control Policy will invest an additional US$ 1 Mn in its Real Deal on Fentanyl campaign with the Ad Council. The initiative tries to reach out to young people, who are the fastest-growing age group in the U.S. for opioid overdoses.